{
    "clinical_study": {
        "@rank": "30223", 
        "arm_group": {
            "arm_group_label": "Tracer", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study to determine the optimum time and dose to draw blood samples using a\n      tracer for HDL kinetics."
        }, 
        "brief_title": "Dose of Labeled Cholesterol for Kinetics: A Pilot Study", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lipid Metabolism", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Healthy men and women ages 18 - 50\n\n        Exclusion Criteria:\n\n          -  Cardiovascular disease\n\n          -  Metabolic disease\n\n          -  Hematologic disorder\n\n          -  Liver or kidney disease\n\n          -  phenylketonuria\n\n          -  Currently taking lipid lowering medications or any other drugs that could affect\n             lipid metabolism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065817", 
            "org_study_id": "13-004890"
        }, 
        "intervention": {
            "arm_group_label": "Tracer", 
            "intervention_name": "stable isotope of cholesterol", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lipid", 
            "Apolipoproteins", 
            "Cardiovascular disease risks"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "dunagan.kelly@mayo.edu", 
                "last_name": "Kelly Dunagan, RN", 
                "phone": "507-255-0111"
            }, 
            "contact_backup": {
                "email": "Smailovic.Almira@mayo.edu", 
                "last_name": "Almira Smailovic, BS", 
                "phone": "5072557536"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": {
                "last_name": "John M Miles, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "John M Miles, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "13C3 cholesterol, which is labeled with a stable isotope, will be administered orally. Blood samples will be taken every 4-6 hours for 72 hours for the measurement of stable isotopic enrichment in cholesterol using gas chromatography-mass spectrometry. The study has a dual purpose: to determine the optimum oral dose of isotope, and to determine the time of peak enrichment in plasma cholesterol.", 
            "measure": "Incorporation of orally administered 13C3 cholesterol into plasma cholesterol", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065817"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "John Miles", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}